LearnGlossaryMarketStocksSuperinvestorsSign in

GNLX

Genelux Corporation

Healthcare · $111M market cap

Verdict

We can't put a fair value on GNLX right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-62.8% a year✗
Sales growth-93.5% a year✗
Free cash flow growth—?
Return on invested capital32.0%✓

Follow GNLX

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Aug 31, 2026: no open-market purchases and 3 sales worth $147K. Why purchases matter

Sales

Yu Yong

Chief Scientific Officer · 2026-08-31

Sold

$27K

Zindrick Thomas

President and CEO · 2026-08-31

Sold

$92K

Cappello Joseph

Chief Technical Officer · 2026-08-31

Sold

$28K

About Genelux Corporation

Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works